Recent in vivo advances of spirocyclic scaffolds for drug discovery
- 25 March 2022
- journal article
- other
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 17 (6) , 603-618
Abstract
Spirocyclic scaffolds are an exceptional tool in drug design, allowing fine-tuning of a molecule’s conformational and physicochemical properties. As it expands and diversifies, so does the number o...Keywords
Funding Information
- Foundation for Science and Technology
This publication has 76 references indexed in Scilit:
- Synthesis and evaluation of spiroisoxazoline oxindoles as anticancer agentsBioorganic & Medicinal Chemistry, 2014
- Synthesis, in Vitro, and in Cell Studies of a New Series of [Indoline-3,2′-thiazolidine]-Based p53 ModulatorsJournal of Medicinal Chemistry, 2013
- A Potent Small-Molecule Inhibitor of the MDM2–p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in MiceJournal of Medicinal Chemistry, 2013
- Inhibitors of the p53/hdm2 protein–protein interaction—path to the clinicBioorganic & Medicinal Chemistry Letters, 2013
- Buspirone: What is it all about?Brain Research, 2012
- Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discoveryCell Cycle, 2010
- Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasivenessNature Chemical Biology, 2009
- Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibitionProceedings of the National Academy of Sciences, 2008
- Depot fluspirilene for schizophreniaCochrane Database of Systematic Reviews, 2007
- Extension and revision of the nomenclature for spiro compoundsPure and Applied Chemistry, 1999